Lowy Seminar Series 2018
A/Prof Guillaume Lessene, PhD
Walter & Eliza Hall Institute of Medical Research, Melbourne
A/Prof Guillaume Lessene heads the ACRF Chemical Biology Division at WEHI, Melbourne. A/Prof Lessene is an organic chemist, completing his PhD at the University of Bordeaux. Following postdoctoral studies at the Pennsylvania State University, he moved to WEHI in 2001. His research focuses on developing small molecules that target the apoptotic and necroptotic cell death pathway. His work on targeting the BCL-2 family proteins leads to the development of Venetoclax, the first BH3 mimetic to be approved by the FDA for the treatment of CLL. He has been awarded the Biota Award in 2009, the WEHI Burnet Prize in 2013, and the inaugural Sir John Dixon Hughes Medal for Medical Research Innovation from NFMRI. A/Prof Lessene also received the 2016 Johnson & Johnson Eureka Prize and the 2018 ATSE’s Clunies-Ross Knowledge Commercialisation Award.